← FDA ENFORCEMENT
D-0043-2025Class II
Cipla USA, Inc.
What this record is not
A recall record is reproduced as FDA published it, and the classification is FDA’s. SPEQ adds no interpretation, and a recall concerns the products and dates in the record — it is not a statement about a company’s other products or its current status.
Recalling firm
Cipla USA, Inc.
Product type
Drug
Status
Ongoing
Report date
2024-11-20
Distribution
USA nationwide.
Firm state
NJ
Product quantity
1,875 boxes (cipla and exlan)
Initiated by
Voluntary: Firm initiated
Reason for recall
Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.
Product description
Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98
Code / lot info
Lot # NB240316, Exp 12/31/25
Data: U.S. FDA. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Open the enforcement explorer →